-
公开(公告)号：US20190177405A1
公开(公告)日：2019-06-13
申请号：US16321020
申请日：2017-07-26
Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventor： Simeon CUA , Andre Boon Hwa CHOO , Heng Liang TAN , Wey Jia FONG , Vanessa Mei Yee DING , Leonard Wen Yan LEONG
IPC: C07K16/18 , A61K39/395 , A61K31/282 , A61K31/337 , A61K31/5377 , A61K47/68 , C07K14/705 , A61K38/17
Abstract: The present invention relates to an antigen-binding protein, preferably a monoclonal antibody, against annexin A2 (ANXA2), comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequence GYSITSGYSWH, a VHCDR2 of sequence YIHYSGSTKYNPSLKS and a VHCDR3 of sequence GSNYGFDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSNDQKNYLA, a VLCDR2 of sequence WASIRES, and a VLCDR3 of sequence QQYYIYPLT. Also provided is an ANXA2 binding protein comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequence VYSITSGYSWH; a VHCDR2 of sequence YIHYSGSTKYNPSLKS, and a VHCDR3 of sequence GTDNAVDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSSNQKNYLA, a VLCDR2 of sequence WASSRES, and a VLCDR3 of sequence QQYYIYPLT. The antibodies preferably bind to an N-linked glycan on ANXA2, and are internalised upon binding. They may be conjugated with cytotoxins and may be used in the treatment or detection of cancer.
-
公开(公告)号：US20240018221A1
公开(公告)日：2024-01-18
申请号：US18034289
申请日：2021-10-26
Applicant: Agency for Science, Technology and Research
Inventor： Wey Jia FONG , Boon Hwa CHOO , Mei Yee Vanessa DING , Chui Ping CHIN
CPC classification number: C07K16/18 , A61K2039/505 , A61P35/00
Abstract: The invention relates generally to antigen-binding molecules that specifically bind to Myosin Heavy Chain 9 (MYH9) and uses thereof for the treatment of specific cancers, such as mast cell tumors. In one embodiment, the MYH9 is canine MYH9 and the antigen-binding molecule is an antibody. In another embodiment, the antigen-binding molecule is conjugated to a toxin, for the treatment of canine mast cell tumors.
-
公开(公告)号：US20200317812A1
公开(公告)日：2020-10-08
申请号：US16303657
申请日：2017-05-22
Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventor： Mei Yee Vanessa DING , Boon Hwa Andre CHOO , Wey Jia FONG
Abstract: The present invention relates to antigen-binding proteins, or antigen-binding fragments thereof that bind to a glycan on the AXL receptor tyrosine kinase. The present invention also relates to antigen-binding proteins, or antigen-binding fragment conjugated to a radioisotope or cytotoxin, and wherein said antigen-binding proteins, or antigen-binding fragment is internalised into a cell upon binding to AXL receptor tyrosine kinase. Compositions comprising a physiologically acceptable carrier and a therapeutically effective amount of the antigen-binding protein, or antigen-binding fragment thereof, therapeutic use of the antigen-binding protein, or antigen-binding fragment thereof, methods for detecting cancer as well as kits when used in such methods are also provided.
-
公开(公告)号：US20240132595A1
公开(公告)日：2024-04-25
申请号：US18275519
申请日：2022-01-28
Applicant: Agency for Science, Technology and Research
Inventor： Chui Ping Angela CHIN , Boon Hwa Andre CHOO , Wey Jia FONG , Mei Yee Vanessa DING
CPC classification number: C07K16/2833 , A61K47/68031 , A61P35/00 , C07K2317/24 , C07K2317/565
Abstract: The invention relates to antigen-binding molecules that specifically bind to MHC Class I DLA-12 antigen. In one embodiment, the antigen-binding molecule is an antibody that specifically binds to canine MHC Class I DLA-12 antigen. Chimeric molecules of the antibody conjugated to another heterologous moiety are also provided. In one embodiment, the heterologous moiety is monomethyl auristatin E (MMAE). A method of inhibiting cancer using the antibody or the chimeric molecule thereof is also provided. In another embodiment, the antibody-MMAE conjugate suppresses tumour development in a murine model of B cell lymphoma.
-
-
-
Search Results
4
records
(took 0.014 seconds)
